## 2 Methods  
A retrospective medical chart review was performed for 55 eyes from 55 patients with PCV treated by a combination therapy of either IVA or IVR with prompt PDT at Far Eastern Memorial Hospital in Taiwan from August 2015 to November 2018. There were 30 patients in the IVA/PDT group treated from August 2015 to December 2017, and 25 patients in the IVR/PDT group from January to November 2018. This study was approved by the Institutional Review Board of Far Eastern Memorial Hospital (ethical approval office reference number: FEMH-107160-E), and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants before treatment.  
Prior to the initial treatments, all patients received comprehensive ophthalmic examinations, including measurements of (BCVA) using Snellen E chart, intraocular pressure, slit-lamp biomicroscopy, color fundus photography, spectral-domain optical coherence tomography (SD-OCT) (RTVue, Optovue Inc., Fremont, CA, USA), fundus fluorescein, and indocyanine green angiography (FA/ICGA) (HRA, Heidelberg Engineering, Heidelberg, Germany). Central retinal thickness (CRT) was measured by SD-OCT.  
The diagnosis of PCV was made by the presence of polypoidal choroidal vascular lesions with or without abnormal vascular networks on ICGA. Exclusion criteria included patients with diabetic retinopathy, retinal vessel occlusion, rhegatogenous retinal detachment, uveitis, glaucoma, or pregnancy. If the patient had PCV of both eyes, the eye treated first was included. If a patient received treatment for both eyes simultaneously, the eye with worse BCVA was included for analysis.  
All subjects received combination therapy with IVI of affibercpt (2.0 mg in 0.05 mL) or ranibizumab (0.5 mg in 0.05 mL) followed by standard PDT within a week of the IVI. The PDT was administered according to the standard protocol [19]. After the initial treatment, follow-up examinations including BCVA, slit-lamp biomicroscopy, fundus examination, and OCT were performed every 3 months, and all patients were followed for at least 24 months. Angiographic regression of polypoidal vascular lesions in ICGA was evaluated three months after the initial treatment.  
Retreatment included IVI monotherapy or combination therapy. In the IVA/PDT group, repeated IVA monotherapy was administered in cases with recurrent or persistent submacular or intramacular fluid but complete regression of choroidal vascular polyps. Repeated combination therapy with IVA and PDT was performed in cases having partial or no polyp regression without dry macula. Repeated IVR alone or combined with PDT was performed using the same protocol in recurrent or refractory cases in the IVR/PDT group. Numbers of additional IVI monotherapy or additional combination therapy were recorded and the units were times. The retreatment rate was defined as patients receiving retreatment of all patients in each group.  
Baseline data and treatment outcomes were compared between the two groups. Primary outcomes were the changes in BCVA and the rate of complete polyp regression. Secondary outcome measures were the changes in CRT, and the rate of dry macula. The BCVA was converted from a Snellen E chart to a logarithm of the minimum angle of resolution (LogMAR) for statistical analysis. Patients with BCVA gain or loss \(\geq\) 0.3 LogMAR units were recorded. Dry macula means no subretinal and intraretinal fluid at macula on OCT.  
Statistical analysis was performed using SPSS (V. 20.0, IBM, Armonk, New York, NY, USA). A paired \(t\)-test was used to compare LogMAR BCVA and CRT before and after treatment. An independent \(t\)-test was used to evaluate differences of continuous variables between the two groups. A chi-square test was used to evaluate differences of categorical variables between the two groups. [PERSON]'s correlation coefficient was performed to investigate the correlations of clinical factors and visual outcome or retreatment. A \(p\)-value less than 0.05 was considered a statistical significance.